方法：选取原发性开角型青光眼或高眼压患者18例32眼。患者均局部用曲伏前列素滴眼液，每晚滴1次。用药前及用药后1，2，3mo行症状评分及基础泪液分泌量测定(Schirmer Ⅰ test ，SⅠt)、角膜荧光素染色(corneal fluorescein staining，FL)、泪膜破裂时间(tear break-up time， BUT)。

结果：全部患者用药前患者症状评分、FL的平均值为1.34±1.56，0.44±0.73，用药后1，2，3mo分别为2.75±1.63，1.08±0.84； 5.10±1.68，1.53±0.67； 6.33±1.40，1.98±0.50。用药后1，2，3mo患者症状评分、FL均显著高于用药前(P=0.00)，且逐渐增加。全部患者用药前患者症状BUT，SⅠt的平均值为(7.76±0.92s)，(8.47±2.73mm/5min)，用药后1，2，3mo分别(7.08±1.15s)，(7.73±3.44mm/5min)；(5.59±1.33s)，(6.82±3.05mm/5min)；(4.29±1.87s)，(6.04±3.15mm/5min)。用药后1，2，3mo患者BUT 值和SⅠt值均显著低于用药前水平(P=0.00)，且逐渐减低。

结论：短期使用曲伏前列素滴眼液即加重患者角膜刺激症状，泪膜稳定性下降， 泪液分泌减少。

METHODS: Eighteen patients(32 eyes)with primary open-angle glaucoma or ocular hypertension were all treated with Travoprost eyedrops once every night. The symptom score, Schirmer's test(SⅠt), corneal fluorescein staining(FL), tear film break-up time(BUT), were observed before the treatment and 1, 2 and 3mo after the treatment.

RESULTS: The average symptom score, FL of all patients were 1.34±1.56 and 0.44±0.73 before the treatment, and 2.75±1.63, 1.08±0.84; 5.10±1.68, 1.53±0.67; 6.33±1.40, 1.98±0.50 respectively after 1, 2 and 3mo of the treatment. There was significant increase in symptom score and FL after the treatment for 1, 2 and 3mo(P=0.00). The average BUT, SⅠt of all patients were(7.76±0.92s),(8.47±2.73mm/5min)before the treatment, and(7.08±1.15s),(7.73±3.44mm/5min);(5.59±1.33s),(6.82±3.05mm/5min);(4.29±1.87s),(6.04±3.15mm/5min)respectively after 1, 2 and 3mo of the treatment. There was significant decrease in BUT and ST after the treatment for 1, 2 and 3mo(P=0.00).

CONCLUSION: Travoprost eyedrops can obviously aggravate patients' corneal irritation after treatment. Our results show abnormal decreased tear secretion and stability of tear film induced by Travoprost eyedrops over the short term.